Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berlim 25/20 in type 2 diabetes and dyslipidemia
NCT04602754Phase 3Recruiting
- Sponsor
- EMS
- Start
- Dec 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Berlim 25/20 in type 2 diabetes mellitus (T2DM), dyslipidemia, sponsored by EMS. Started Dec 2023; status: recruiting.
02
Drugs
Berlim 25/20
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on NCT04602754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04602754.